Trade

with

Impax Laboratories Inc
(NASDAQ: IPXL)
AdChoices
=
27.80
0.00
0.00%
After Hours :
27.80
0.00
0.00%

Open

27.92

Previous Close

27.80

Volume (Avg)

322.17k (732.55k)

Day's Range

27.54-28.00

52Wk Range

19.67-31.04

Market Cap.

1.97B

Dividend Rate ( Yield )

-

Beta

1.17

Shares Outstanding

70.70M

P/E Ratio (EPS)

60.98 (0.46)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 511.50M

    • Net Income

    • 101.26M

    • Market Cap.

    • 1.97B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 5.87

    • PEG (Price/Earnings Growth) Ratio

    • 1.61

    • Beta

    • 1.17

    • Forward P/E

    • 34.84

    • Price/Sales

    • 3.58

    • Price/Book Value

    • 2.26

    • Price/Cash flow

    • -277.78

      • EBITDA

      • 183.36M

      • Return on Capital %

      • 3.06

      • Return on Equity %

      • 3.77

      • Return on Assets %

      • 3.06

      • Book Value/Share

      • 12.29

      • Shares Outstanding

      • 70.70M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 26.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • 0.80

        • Cashflow Estimate

        • 1.13

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 45.10

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • 81.20

          • -26.33

          • Net Income

            Q/Q (last year)

          • 524.20

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 19.48

          • -5.42

          • Net Income

            5-Year Annual Average

          • 40.20

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 46.27

            • 64.72

            • Pre-Tax Margin

            • 8.74

            • 13.77

            • Net Profit Margin

            • 5.87

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 50.30

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 25.30

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 16.90

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 4.60

              • 1.52

              • Quick Ratio

              • 3.69

              • 0.87

              • Interest Coverage

              • 397.97

              • 6.77

              • Leverage Ratio

              • 1.22

              • 1.91

              • Book Value/Share

              • 12.29

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 59.17

                • 65.79

                • P/E Ratio 5-Year High

                • 68.13

                • 237.47

                • P/E Ratio 5-Year Low

                • 0.40

                • 19.71

                • Price/Sales Ratio

                • 3.48

                • 3.69

                • Price/Book Value

                • 2.20

                • 3.46

                • Price/Cash Flow Ratio

                • -277.78

                • 22.12

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 3.77

                        (25.80)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • 3.06

                        (14.40)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • 3.78

                        (25.40)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • 32.57k

                      • 27.79k

                      • Inventory Turnover

                      • 3.40

                      • 1.80

                      • Asset Turnover

                      • 0.52

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -6.39M
                      Operating Margin
                      -1.25
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -277.78
                      Ownership

                      Institutional Ownership

                      89.44%

                      Top 10 Institutions

                      40.06%

                      Mutual Fund Ownership

                      50.70%

                      Float

                      84.32%

                      5% / Insider Ownership

                      2.45%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • PowerShares Dynamic Pharmaceuticals Port

                      •  

                        1,663,929

                      • 0.00

                      • 2.76

                      • iShares Core S&P Small-Cap (AU)

                      •  

                        1,330,398

                      • 0.20

                      • 2.21

                      • SPDR® S&P Pharmaceuticals ETF

                      •  

                        1,325,520

                      • 0.00

                      • 2.20

                      • Vanguard Small Cap Index

                      •  

                        1,166,672

                      • 0.56

                      • 1.65

                      • Fidelity® Mid-Cap Stock Fund

                      •  

                        1,101,400

                      • 0.00

                      • 1.56

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,080,100

                      • 0.70

                      • 1.53

                      • iShares Russell 2000 (AU)

                      •  

                        1,043,203

                      • -1.46

                      • 1.73

                      • iShares Nasdaq Biotechnology

                      •  

                        913,705

                      • -0.47

                      • 1.52

                      • Fidelity® Value Fund

                      •  

                        860,155

                      • -8.76

                      • 1.22

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Orbimed Advisors, LLC

                      •  

                        5,415,600

                      • +1.31%

                      • 7.66

                      • BlackRock Fund Advisors

                      •  

                        4,682,088

                      • -5.36%

                      • 6.62

                      • Vanguard Group, Inc.

                      •  

                        4,402,564

                      • +0.02%

                      • 6.23

                      • Fidelity Management and Research Company

                      •  

                        3,703,932

                      • -11.67%

                      • 5.24

                      • State Street Corp

                      •  

                        2,348,197

                      • +12.23%

                      • 3.32

                      • Jennison Associates LLC

                      •  

                        1,721,415

                      • +21.88%

                      • 2.43

                      • Columbia Mangmt Investment Advisers, LLC

                      •  

                        1,574,550

                      • -3.54%

                      • 2.23

                      • Dimensional Fund Advisors, Inc.

                      •  

                        1,430,292

                      • +3.50%

                      • 2.02

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Slow Growth

                      Style

                      Small Growth

                      Impax Laboratories, Inc., is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the ...moredevelopment, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as ‘generics’ in addition to the development and marketing of branded products. The Company operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Co...morempany develops, manufacture, sell and distribute specialty generic pharmaceuticals. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the ‘Global products’ sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the ‘Private Label’ sales channel, for generic pharmaceutical over-the-counter (‘OTC’) and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the ‘Rx Partner’ sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the ‘OTC Partner’ sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig(r) (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). The Company’s Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system (‘CNS’) disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Generic pharmaceutical product development activities include 64 Abbreviated New Drug Applications (ANDAs) approved by the U.S. Food and Drug Administration, which include generic versions of brand name pharmaceuticals such as Brethine(r), Florinef(r), Minocin(r), Claritin-D(r).12-hour, Claritin-D(r) 24-hour, Wellbutrin SR(r), Wellbutrin XL(r), Ditropan XL(r), Depakote ER(r) and Prilosec(r).; 35 applications pending at the FDA, including 3 tentatively approved. The Company’s main competitors are Teva Pharmaceutical Industries Ltd., Actavis, Inc., Mylan Inc., Ranbaxy Laboratories Ltd., Lannett Company, Inc., Sandoz, Inc., and Par Pharmaceutical Companies, Inc. The manufacturing and distribution of pharmaceutical products are subject to regulation by the federal government, through the FDA and the Drug Enforcement Administration (‘DEA’), and to a lesser extent by state and local governments.lessless

                      Key People

                      G. Frederick Wilkinson

                      President/CEO/Director

                      Robert L. Burr

                      Chairman of the Board/Director

                      Dr. Larry Hsu,PhD

                      Co-Founder/Director

                      Mr. Bryan M. Reasons

                      CFO/Chief Accounting Officer/Senior VP, Divisional

                      Allen Chao,PhD

                      Director

                      • Impax Laboratories Inc

                      • 30831 Huntwood Avenue

                      • Hayward, CA 94544

                      • USA.Map

                      • Phone: +1 510 476-2000

                      • Fax: +1 510 471-3200

                      • impaxlabs.com

                      Incorporated

                      1995

                      Employees

                      973

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: